CN113583107B - CRIg功能区蛋白变体及其应用 - Google Patents
CRIg功能区蛋白变体及其应用 Download PDFInfo
- Publication number
- CN113583107B CN113583107B CN202110856994.7A CN202110856994A CN113583107B CN 113583107 B CN113583107 B CN 113583107B CN 202110856994 A CN202110856994 A CN 202110856994A CN 113583107 B CN113583107 B CN 113583107B
- Authority
- CN
- China
- Prior art keywords
- crig
- val
- leu
- functional region
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 69
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 68
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 43
- 230000024203 complement activation Effects 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 230000002159 abnormal effect Effects 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 29
- 239000013604 expression vector Substances 0.000 claims description 16
- 230000031978 negative regulation of complement activation Effects 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 abstract description 33
- 230000000295 complement effect Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 14
- 230000005764 inhibitory process Effects 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 9
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 description 63
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 45
- 235000001014 amino acid Nutrition 0.000 description 26
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 24
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 230000004913 activation Effects 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 102100022133 Complement C3 Human genes 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 7
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 description 7
- 230000004154 complement system Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 108010061238 threonyl-glycine Proteins 0.000 description 7
- SQKPKIJVWHAWNF-DCAQKATOSA-N Arg-Asp-Lys Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O SQKPKIJVWHAWNF-DCAQKATOSA-N 0.000 description 6
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 6
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 6
- LFAUVOXPCGJKTB-DCAQKATOSA-N Arg-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N LFAUVOXPCGJKTB-DCAQKATOSA-N 0.000 description 6
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 6
- DINOVZWPTMGSRF-QXEWZRGKSA-N Asp-Pro-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O DINOVZWPTMGSRF-QXEWZRGKSA-N 0.000 description 6
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 6
- DRXOWZZHCSBUOI-YJRXYDGGSA-N Cys-Thr-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CS)N)O DRXOWZZHCSBUOI-YJRXYDGGSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MLZRSFQRBDNJON-GUBZILKMSA-N Gln-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MLZRSFQRBDNJON-GUBZILKMSA-N 0.000 description 6
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 6
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 6
- SOEXCCGNHQBFPV-DLOVCJGASA-N Gln-Val-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SOEXCCGNHQBFPV-DLOVCJGASA-N 0.000 description 6
- VXKCPBPQEKKERH-IUCAKERBSA-N Gly-Arg-Pro Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O VXKCPBPQEKKERH-IUCAKERBSA-N 0.000 description 6
- ISSDODCYBOWWIP-GJZGRUSLSA-N Gly-Pro-Trp Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O ISSDODCYBOWWIP-GJZGRUSLSA-N 0.000 description 6
- WJGSTIMGSIWHJX-HVTMNAMFSA-N His-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N WJGSTIMGSIWHJX-HVTMNAMFSA-N 0.000 description 6
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 6
- XLXPYSDGMXTTNQ-DKIMLUQUSA-N Ile-Phe-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(O)=O XLXPYSDGMXTTNQ-DKIMLUQUSA-N 0.000 description 6
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 6
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 6
- TUSOIZOVPJCMFC-FXQIFTODSA-N Met-Asp-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O TUSOIZOVPJCMFC-FXQIFTODSA-N 0.000 description 6
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 6
- MUARUIBTKQJKFY-WHFBIAKZSA-N Ser-Gly-Asp Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MUARUIBTKQJKFY-WHFBIAKZSA-N 0.000 description 6
- CLKKNZQUQMZDGD-SRVKXCTJSA-N Ser-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CN=CN1 CLKKNZQUQMZDGD-SRVKXCTJSA-N 0.000 description 6
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 6
- VTVVYQOXJCZVEB-WDCWCFNPSA-N Thr-Leu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O VTVVYQOXJCZVEB-WDCWCFNPSA-N 0.000 description 6
- QFHRUCJIRVILCK-YJRXYDGGSA-N Tyr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O QFHRUCJIRVILCK-YJRXYDGGSA-N 0.000 description 6
- PHZGFLFMGLXCFG-FHWLQOOXSA-N Val-Lys-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N PHZGFLFMGLXCFG-FHWLQOOXSA-N 0.000 description 6
- RYQUMYBMOJYYDK-NHCYSSNCSA-N Val-Pro-Glu Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RYQUMYBMOJYYDK-NHCYSSNCSA-N 0.000 description 6
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 6
- UEXPMFIAZZHEAD-HSHDSVGOSA-N Val-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N)O UEXPMFIAZZHEAD-HSHDSVGOSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 108010079547 glutamylmethionine Proteins 0.000 description 6
- 108010017391 lysylvaline Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010080629 tryptophan-leucine Proteins 0.000 description 6
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 6
- JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 5
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 5
- YXQCLIVLWCKCRS-RYUDHWBXSA-N Gln-Gly-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N)O YXQCLIVLWCKCRS-RYUDHWBXSA-N 0.000 description 5
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 5
- VLOLPWWCNKWRNB-LOKLDPHHSA-N Gln-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VLOLPWWCNKWRNB-LOKLDPHHSA-N 0.000 description 5
- TZOVVRJYUDETQG-RCOVLWMOSA-N Gly-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN TZOVVRJYUDETQG-RCOVLWMOSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 3
- 229960002224 eculizumab Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- ZEDBMCPXPIYJLW-XHNCKOQMSA-N Asp-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O ZEDBMCPXPIYJLW-XHNCKOQMSA-N 0.000 description 2
- 102220519056 Conserved oligomeric Golgi complex subunit 3_A17D_mutation Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 108010047295 complement receptors Proteins 0.000 description 2
- 102000006834 complement receptors Human genes 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102200103621 rs267607030 Human genes 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710131943 40S ribosomal protein S3a Proteins 0.000 description 1
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 description 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
- GFBLJMHGHAXGNY-ZLUOBGJFSA-N Ala-Asn-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O GFBLJMHGHAXGNY-ZLUOBGJFSA-N 0.000 description 1
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 1
- JPOQZCHGOTWRTM-FQPOAREZSA-N Ala-Tyr-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPOQZCHGOTWRTM-FQPOAREZSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- YFWTXMRJJDNTLM-LSJOCFKGSA-N Arg-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFWTXMRJJDNTLM-LSJOCFKGSA-N 0.000 description 1
- RIQBRKVTFBWEDY-RHYQMDGZSA-N Arg-Lys-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RIQBRKVTFBWEDY-RHYQMDGZSA-N 0.000 description 1
- UULLJGQFCDXVTQ-CYDGBPFRSA-N Arg-Pro-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UULLJGQFCDXVTQ-CYDGBPFRSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- RCENDENBBJFJHZ-ACZMJKKPSA-N Asn-Asn-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCENDENBBJFJHZ-ACZMJKKPSA-N 0.000 description 1
- DPWDPEVGACCWTC-SRVKXCTJSA-N Asn-Tyr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O DPWDPEVGACCWTC-SRVKXCTJSA-N 0.000 description 1
- JGDBHIVECJGXJA-FXQIFTODSA-N Asp-Asp-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JGDBHIVECJGXJA-FXQIFTODSA-N 0.000 description 1
- WWOYXVBGHAHQBG-FXQIFTODSA-N Asp-Met-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O WWOYXVBGHAHQBG-FXQIFTODSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- PLOKOIJSGCISHE-BYULHYEWSA-N Asp-Val-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLOKOIJSGCISHE-BYULHYEWSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- VIRYODQIWJNWNU-NRPADANISA-N Cys-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N VIRYODQIWJNWNU-NRPADANISA-N 0.000 description 1
- ZMWOJVAXTOUHAP-ZKWXMUAHSA-N Cys-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N ZMWOJVAXTOUHAP-ZKWXMUAHSA-N 0.000 description 1
- RWVBNRYBHAGYSG-GUBZILKMSA-N Cys-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)N RWVBNRYBHAGYSG-GUBZILKMSA-N 0.000 description 1
- YNJBLTDKTMKEET-ZLUOBGJFSA-N Cys-Ser-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O YNJBLTDKTMKEET-ZLUOBGJFSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- PGPJSRSLQNXBDT-YUMQZZPRSA-N Gln-Arg-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O PGPJSRSLQNXBDT-YUMQZZPRSA-N 0.000 description 1
- CXFUMJQFZVCETK-FXQIFTODSA-N Gln-Cys-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O CXFUMJQFZVCETK-FXQIFTODSA-N 0.000 description 1
- NPTGGVQJYRSMCM-GLLZPBPUSA-N Gln-Gln-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPTGGVQJYRSMCM-GLLZPBPUSA-N 0.000 description 1
- JHPFPROFOAJRFN-IHRRRGAJSA-N Gln-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O JHPFPROFOAJRFN-IHRRRGAJSA-N 0.000 description 1
- QQAPDATZKKTBIY-YUMQZZPRSA-N Gln-Gly-Met Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O QQAPDATZKKTBIY-YUMQZZPRSA-N 0.000 description 1
- PAOHIZNRJNIXQY-XQXXSGGOSA-N Gln-Thr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PAOHIZNRJNIXQY-XQXXSGGOSA-N 0.000 description 1
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 1
- ZPASCJBSSCRWMC-GVXVVHGQSA-N Glu-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N ZPASCJBSSCRWMC-GVXVVHGQSA-N 0.000 description 1
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 1
- JYXKPJVDCAWMDG-ZPFDUUQYSA-N Glu-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)N JYXKPJVDCAWMDG-ZPFDUUQYSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 1
- WJZLEENECIOOSA-WDSKDSINSA-N Gly-Asn-Gln Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O WJZLEENECIOOSA-WDSKDSINSA-N 0.000 description 1
- LLXVQPKEQQCISF-YUMQZZPRSA-N Gly-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN LLXVQPKEQQCISF-YUMQZZPRSA-N 0.000 description 1
- QPDUVFSVVAOUHE-XVKPBYJWSA-N Gly-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(O)=O QPDUVFSVVAOUHE-XVKPBYJWSA-N 0.000 description 1
- NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- RIYIFUFFFBIOEU-KBPBESRZSA-N Gly-Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 RIYIFUFFFBIOEU-KBPBESRZSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- TVMNTHXFRSXZGR-IHRRRGAJSA-N His-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O TVMNTHXFRSXZGR-IHRRRGAJSA-N 0.000 description 1
- STGQSBKUYSPPIG-CIUDSAMLSA-N His-Ser-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 STGQSBKUYSPPIG-CIUDSAMLSA-N 0.000 description 1
- XGBVLRJLHUVCNK-DCAQKATOSA-N His-Val-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O XGBVLRJLHUVCNK-DCAQKATOSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 1
- LJKDGRWXYUTRSH-YVNDNENWSA-N Ile-Gln-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N LJKDGRWXYUTRSH-YVNDNENWSA-N 0.000 description 1
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 1
- WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 description 1
- NJGXXYLPDMMFJB-XUXIUFHCSA-N Ile-Val-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N NJGXXYLPDMMFJB-XUXIUFHCSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 1
- PRZVBIAOPFGAQF-SRVKXCTJSA-N Leu-Glu-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O PRZVBIAOPFGAQF-SRVKXCTJSA-N 0.000 description 1
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 1
- FMEICTQWUKNAGC-YUMQZZPRSA-N Leu-Gly-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O FMEICTQWUKNAGC-YUMQZZPRSA-N 0.000 description 1
- SEMUSFOBZGKBGW-YTFOTSKYSA-N Leu-Ile-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SEMUSFOBZGKBGW-YTFOTSKYSA-N 0.000 description 1
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 1
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 1
- HGUUMQWGYCVPKG-DCAQKATOSA-N Leu-Pro-Cys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N HGUUMQWGYCVPKG-DCAQKATOSA-N 0.000 description 1
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 1
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 1
- NCZIQZYZPUPMKY-PPCPHDFISA-N Lys-Ile-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NCZIQZYZPUPMKY-PPCPHDFISA-N 0.000 description 1
- XATKLFSXFINPSB-JYJNAYRXSA-N Lys-Tyr-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O XATKLFSXFINPSB-JYJNAYRXSA-N 0.000 description 1
- VWPJQIHBBOJWDN-DCAQKATOSA-N Lys-Val-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O VWPJQIHBBOJWDN-DCAQKATOSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BVXXDMUMHMXFER-BPNCWPANSA-N Met-Ala-Tyr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVXXDMUMHMXFER-BPNCWPANSA-N 0.000 description 1
- RBGLBUDVQVPTEG-DCAQKATOSA-N Met-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCSC)N RBGLBUDVQVPTEG-DCAQKATOSA-N 0.000 description 1
- NSMXRFMGZYTFEX-KJEVXHAQSA-N Met-Thr-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCSC)N)O NSMXRFMGZYTFEX-KJEVXHAQSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- DFEVBOYEUQJGER-JURCDPSOSA-N Phe-Ala-Ile Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O DFEVBOYEUQJGER-JURCDPSOSA-N 0.000 description 1
- XMQSOOJRRVEHRO-ULQDDVLXSA-N Phe-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 XMQSOOJRRVEHRO-ULQDDVLXSA-N 0.000 description 1
- APZNYJFGVAGFCF-JYJNAYRXSA-N Phe-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(O)=O APZNYJFGVAGFCF-JYJNAYRXSA-N 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- LXVLKXPFIDDHJG-CIUDSAMLSA-N Pro-Glu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O LXVLKXPFIDDHJG-CIUDSAMLSA-N 0.000 description 1
- ULIWFCCJIOEHMU-BQBZGAKWSA-N Pro-Gly-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 ULIWFCCJIOEHMU-BQBZGAKWSA-N 0.000 description 1
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 1
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 1
- MRYUJHGPZQNOAD-IHRRRGAJSA-N Pro-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 MRYUJHGPZQNOAD-IHRRRGAJSA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- GHPQVUYZQQGEDA-BIIVOSGPSA-N Ser-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N)C(=O)O GHPQVUYZQQGEDA-BIIVOSGPSA-N 0.000 description 1
- IXUGADGDCQDLSA-FXQIFTODSA-N Ser-Gln-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N IXUGADGDCQDLSA-FXQIFTODSA-N 0.000 description 1
- YQQKYAZABFEYAF-FXQIFTODSA-N Ser-Glu-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQQKYAZABFEYAF-FXQIFTODSA-N 0.000 description 1
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- WEQAYODCJHZSJZ-KKUMJFAQSA-N Ser-His-Tyr Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 WEQAYODCJHZSJZ-KKUMJFAQSA-N 0.000 description 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 1
- UQGAAZXSCGWMFU-UBHSHLNASA-N Ser-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N UQGAAZXSCGWMFU-UBHSHLNASA-N 0.000 description 1
- SGZVZUCRAVSPKQ-FXQIFTODSA-N Ser-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N SGZVZUCRAVSPKQ-FXQIFTODSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- ZUXQFMVPAYGPFJ-JXUBOQSCSA-N Thr-Ala-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN ZUXQFMVPAYGPFJ-JXUBOQSCSA-N 0.000 description 1
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 1
- OHDXOXIZXSFCDN-RCWTZXSCSA-N Thr-Met-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OHDXOXIZXSFCDN-RCWTZXSCSA-N 0.000 description 1
- NDXSOKGYKCGYKT-VEVYYDQMSA-N Thr-Pro-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O NDXSOKGYKCGYKT-VEVYYDQMSA-N 0.000 description 1
- DOBIBIXIHJKVJF-XKBZYTNZSA-N Thr-Ser-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DOBIBIXIHJKVJF-XKBZYTNZSA-N 0.000 description 1
- SOUPNXUJAJENFU-SWRJLBSHSA-N Thr-Trp-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O SOUPNXUJAJENFU-SWRJLBSHSA-N 0.000 description 1
- BZTSQFWJNJYZSX-JRQIVUDYSA-N Thr-Tyr-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O BZTSQFWJNJYZSX-JRQIVUDYSA-N 0.000 description 1
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- WMBFONUKQXGLMU-WDSOQIARSA-N Trp-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WMBFONUKQXGLMU-WDSOQIARSA-N 0.000 description 1
- YTYHAYZPOARHAP-HOCLYGCPSA-N Trp-Lys-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)N YTYHAYZPOARHAP-HOCLYGCPSA-N 0.000 description 1
- UPUNWAXSLPBMRK-XTWBLICNSA-N Trp-Thr-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UPUNWAXSLPBMRK-XTWBLICNSA-N 0.000 description 1
- YCQKQFKXBPJXRY-PMVMPFDFSA-N Trp-Tyr-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCCN)C(=O)O)N YCQKQFKXBPJXRY-PMVMPFDFSA-N 0.000 description 1
- NQJDICVXXIMMMB-XDTLVQLUSA-N Tyr-Glu-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O NQJDICVXXIMMMB-XDTLVQLUSA-N 0.000 description 1
- HDSKHCBAVVWPCQ-FHWLQOOXSA-N Tyr-Glu-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HDSKHCBAVVWPCQ-FHWLQOOXSA-N 0.000 description 1
- NOOMDULIORCDNF-IRXDYDNUSA-N Tyr-Gly-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NOOMDULIORCDNF-IRXDYDNUSA-N 0.000 description 1
- UPODKYBYUBTWSV-BZSNNMDCSA-N Tyr-Phe-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=C(O)C=C1 UPODKYBYUBTWSV-BZSNNMDCSA-N 0.000 description 1
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 1
- ZEVNVXYRZRIRCH-GVXVVHGQSA-N Val-Gln-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N ZEVNVXYRZRIRCH-GVXVVHGQSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 1
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 1
- RTJPAGFXOWEBAI-SRVKXCTJSA-N Val-Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RTJPAGFXOWEBAI-SRVKXCTJSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940121388 complement c3 inhibitor Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- -1 glidants Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010063431 methionyl-aspartyl-glycine Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010020432 prolyl-prolylisoleucine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种CRIg功能区蛋白变体及其应用。所述的CRIg功能区蛋白变体在天然CRIg功能区蛋白序列的基础上进行氨基酸的取代，氨基酸取代位点为17D、19N、28Q、29G、80Q、101P、102D中的一个或多个。本发明提供的CRIg功能区蛋白变体相较于天然序列的CRIg功能区蛋白，对补体激活的抑制功能更强，可应用于制备靶向抑制补体激活的抑制剂或药物，以解决现有CRIg对补体的抑制活性弱的问题，提供疗效更高的产品，以应用于多种与补体异常激活有关疾病的预防和治疗。
Description
技术领域
本发明涉及生物技术和生物医药领域，更具体地说，本发明涉及CRIg功能区蛋白变体及其应用。
背景技术
补体系统是固有免疫系统的重要组成部分，也是获得性免疫的重要调节者，在清除病原体和体内废物方面发挥这重要的免疫监视和组织自稳作用。补体系统是由正常情况下以无活性的酶原形式存在的一系列血清糖蛋白构成的复杂酶级联，其主要通过三条途径激活：由抗原抗体复合物激活的经典途径、自动激活或通过补体识别外源物表面结构介导的替补(旁路)途径、以及主要由微生物表明多糖结构介导的凝集素途径。它们在C3水平合并，其中两种类似的C3转化酶将C3切割成C3a和C3b。
虽然补体系统发挥着重要的免疫监视作用，但越来越多的研究发现，人体许多疾病被证实与补体的过度激活有关，因此，以补体系统为治疗靶点的药物研发，包括补体系统抑制剂受到重视。首个补体特异性抑制剂依库珠单抗(Eculizumab，商品名Soliris)为一种阻断补体终末阶段成分C5激活的单抗，其临床上获得了巨大的成功。但是，依库珠单抗无法阻止补体更上游的C3成分的激活，使得补体仍然被激活，并产生致病效应。补体C3抑制剂比阻止更下游的补体激活(例如依库珠单抗阻止C5的激活)可能是一种更有效更全面的治疗策略。因此，研发更优的补体激活的药物仍然存在巨大的临床需求。
CRIg(也称VSIG4，或Z39IG)是一种仅仅表达于组织驻留的巨噬细胞(如肝脏库否氏细胞)表面的Ig超家族补体受体，在发挥C3蛋白质的补体受体功能之外，通过结合C3b及抑制C3和C5的蛋白水解活化，从而在补体级联反应的早期产生抑制作用——这种抑制作用针对补体的替补激活途经。CRIg主要与C3b的β链结合，两者的接触面较大，C3的MG3、MG4、MG5、MG6和LNK结构域都与CRIg相互作用，其中MG3和MG6贡献最大，分别占总接触界面的30％和40％。
已有研究证明，CRIg融合蛋白通过对补体的抑制，可有效治疗多种疾病，如小鼠关节炎，但由于CRIg对补体的抑制活性较弱，因此，亟需经过研究来进一步增强它的补体抑制活性，以便于未来的临床应用。
发明内容
本发明的目的在于提供了一种CRIg功能区蛋白变体，其相较于天然序列的CRIg功能区蛋白，所述变体对补体激活的抑制作用更强，可应用于制备靶向抑制补体激活的抑制剂或药物，以解决现有CRIg对补体的抑制活性弱的问题，提供疗效更高的药物，以应用于多种与补体异常激活有关疾病的预防和治疗。
基于上述，本发明的第一个目的是提供一种CRIg功能区蛋白变体，所述的CRIg功能区蛋白的氨基酸序列如SEQ ID NO：4所示；所述的CRIg功能区蛋白变体在SEQ ID NO：4序列的基础上进行氨基酸的取代，氨基酸的取代位点为17D、19N、28Q、29G、80Q、101P、102D中的一个或多个；相较于SEQ ID NO：4所示的天然序列的CRIg功能区蛋白，所述的CRIg功能区蛋白变体是补体抑制活性更高的旁路补体途经抑制剂。
优选地，所述变体选自以下(a)～(e)中的任何一种：
(a)将SEQ ID NO：4所示的序列进行A17D位点的氨基酸取代得到的突变体，该突变体的核酸序列如SEQ ID NO：5所示，氨基酸序列如SEQ ID NO：6所示；
(b)将SEQ ID NO：4所示的序列进行A19N位点的氨基酸取代得到的突变体，该突变体的核酸序列如SEQ ID NO：7所示，氨基酸序列如SEQ ID NO：8所示；
(c)将SEQ ID NO：4所示的序列同时进行A28Q和A29G两个位点的氨基酸取代得到的突变体，该突变体的核酸序列如SEQ ID NO：9所示，氨基酸序列如SEQ ID NO：10所示；
(d)将SEQ ID NO：4所示的序列进行A80 Q位点的氨基酸取代得到的突变体，该突变体的核酸序列如SEQ ID NO：11所示，氨基酸序列如SEQ ID NO：12所示；
(e)将SEQ ID NO：4所示的序列同时进行A101P和A102D两个位点的氨基酸取代得到的突变体，该突变体的核酸序列如SEQ ID NO：13所示，氨基酸序列如SEQ ID NO：14所示。
本发明的另一个目的是提供一种核酸，所述的核酸序列编码权利要求1或2所述的CRIg功能区蛋白变体。
本发明的另一个目的是提供一种表达载体，其含有所述的核酸。
本发明的另一个目的是提供一种重组细胞，其含有所述的表达载体或其基因组中包含所述的核酸。
本发明的另一个目的是提供所述的CRIg功能区蛋白变体或编码其的核酸，或所述的表达载体，或所述的重组细胞在制备靶向抑制补体激活的抑制剂中的应用。
本发明的另一个目的是提供所述的CRIg功能区蛋白变体或编码其的核酸，或所述的表达载体，或所述的重组细胞在制备防治与补体异常激活有关疾病的药物中的应用。
本发明的另一个目的是提供一种制备所述的CRIg功能区蛋白变体的方法；
一些实施例中，所述方法包括：培养所述的重组细胞，从而重组表达所述的CRIg功能区蛋白变体。
本发明的另一个目的是提供一种用于靶向抑制补体激活的药物组合物，所述的药物组合物包括：前面任一所述的CRIg功能区蛋白变体或编码其的核酸，或所述的表达载体，或所述的重组细胞；以及药学上或生理学上可接受的载体。
相对于现有技术，本发明的有益效果是：根据CRIg与C3b复合物结构设计出CRIg胞外功能区的多个氨基酸取代位点，最终提供了多个CRIg功能区蛋白变体，相较于天然序列的CRIg功能区蛋白，这些变体对补体激活的抑制功能更强，可应用于制备靶向抑制补体激活的抑制剂或药物，以解决现有CRIg对补体的抑制活性弱的问题，提供疗效更高的药物，以应用于多种与补体异常激活有关疾病的预防和治疗。
附图说明
图1为不同CRIg-Fc-Mutant重组蛋白的电泳鉴定结果图；
图2为测定CRIg-Fc-Mu1变体重组蛋白对补体激活的抑制效果图；
图3为测定CRIg-Fc-Mu2变体重组蛋白对补体激活的抑制效果图；
图4为测定CRIg-Fc-Mu3变体重组蛋白对补体激活的抑制效果图；
图5为测定CRIg-Fc-Mu4变体重组蛋白对补体激活的抑制效果图；
图6为测定CRIg-Fc-Mu5变体重组蛋白对补体激活的抑制效果图。
具体实施方式
以下将结合附图和实施例对本发明的技术方案做进一步说明。
本课题组根据CRIg与C3b复合物结构设计出CRIg胞外功能区的多个氨基酸取代位点，最终提供了多个CRIg功能区蛋白变体，相较于天然序列的CRIg功能区蛋白，这些变体对补体激活的抑制功能更强，可应用于制备靶向抑制补体激活的抑制剂或药物，以解决现有CRIg对补体的抑制活性弱的问题，提供疗效更高的药物，以应用于多种与补体异常激活有关疾病的预防和治疗。
术语
如本发明所用，所述“CRIg胞外功能区”、“CRIg胞外结构域”、“天然序列的CRIg胞外功能区”可以互换使用。
如本发明所用，所述“氨基酸取代”可以是保守氨基酸取代或非保守氨基酸取代。经取代后的CRIg胞外结构域仍具有与取代前相同或相近的功能活性。
例如，所述氨基酸取代可以为非保守取代。所述非保守取代可包括以非保守的形式改变目标蛋白或多肽中的氨基酸残基，例如将具有某种侧链大小或某种特性(例如，亲水性)的氨基酸残基变为具有不同侧链大小或不同特性(例如，疏水性)的氨基酸残基。
所述氨基酸取代也可以为保守取代。所述保守取代可包括以保守的形式改变目标蛋白或多肽中的氨基酸残基，例如将具有某种侧链大小或某种特性(例如，亲水性)的氨基酸残基变为具有相同或相似侧链大小或者相同或相似特性(例如，仍为亲水性)的氨基酸残基。这样的保守取代通常不会对所产生的蛋白质的结构或功能带来很大影响。在本申请中，所述CRIg胞外结构域的氨基酸序列变体可包括不显著改变蛋白质结构或其功能的保守氨基酸取代。
作为示例，下述各组中每组内各氨基酸间的相互取代在本发明中可被认为是保守取代：
(1)具有非极性侧链的氨基酸组：丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、色氨酸和甲硫氨酸；
(2)不带电荷、具有极性侧链的氨基酸组：甘氨酸、丝氨酸、苏氨酸，半胱氨酸，酪氨酸，天冬酰胺和谷氨酰胺。
(3)负电荷、具有极性侧链的酸性氨基酸组：天冬氨酸和谷氨酸。
(4)带正电荷的碱性氨基酸组：赖氨酸、精氨酸和组氨酸。
(5)带苯基的氨基酸组：苯丙氨酸、色氨酸和酪氨酸。
如本发明所用，“药学上可接受的”的成分是适用于人和/或哺乳动物而无过度不良副反应(如毒性)的，即具有合理的效益/风险比的物质。术语“药学上可接受的载体”指用于治疗剂给药的载体，包括各种赋形剂和稀释剂。该术语指这样一些药剂载体：它们本身并不是必要的活性成分，且施用后没有过分的毒性。
本发明根据CRIg(核酸序列如SEQ ID NO：1所示；氨基酸序列如SEQ ID NO：2所示)与C3b复合物结构设计出CRIg胞外功能区的多个氨基酸取代位点，所述的CRIg胞外功能区氨基酸序列为：RPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFLRDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDDRSHYTCEVTWQTPDGNQVVRDKITELRVQK(SEQ ID NO：4)，对应的核酸序列如SEQ ID NO：3所示；并同时示例性的提供了5种CRIg功能区蛋白变体。其中：
(1)将天然的CRIg功能区蛋白序列进行A17D位点氨基酸取代得到的突变体1命名为CRIg-Mu1(氨基酸序列如SEQ ID NO：6所示)；
(2)将天然的CRIg功能区蛋白序列进行A19N位点氨基酸取代得到的突变体2命名为CRIg-Mu2(氨基酸序列如SEQ ID NO：8所示)；
(3)将天然的CRIg功能区蛋白序列同时进行A28Q和A29G两个位点氨基酸取代得到的突变体3命名为CRIg-Mu3(氨基酸序列如SEQ ID NO：10所示)；
(4)将天然的CRIg功能区蛋白序列进行A80Q位点氨基酸取代得到的突变体4命名为CRIg-Mu4(氨基酸序列如SEQ ID NO：12所示)；
(5)将天然的CRIg功能区蛋白序列同时进行A101P和A102D两个位点氨基酸取代得到的突变体5命名为CRIg-Mu5(氨基酸序列如SEQ ID NO：14所示)。
本发明“SEQ ID NO：4所示的CRIg胞外功能区”将G定义为第0位氨基酸，将R定义为第1位氨基酸，依次类推。本发明“进行A17D位点氨基酸取代”表示将氨基酸序列为SEQ IDNO：4所示的CRIg胞外功能区的第17位的天冬氨酸(D)突变成丙氨酸(A)；本发明所述其他位点的氨基酸取代的表述依此类推。另外，
本发明还提供了编码本发明CRIg功能区蛋白变体的核酸序列。其中，编码示例性的5种CRIg功能区蛋白变体的核酸序列分别如SEQ ID NO：5、7、9、11、13所示。
本发明也涉及包含本发明的核酸的载体，以及用本发明的载体或CRIg功能区蛋白变体的编码序列经基因工程产生的宿主细胞(重组细胞)，以及经重组技术产生本发明所述CRIg功能区蛋白变体的方法。
术语“表达载体”指本领域熟知的细菌质粒、噬菌体、酵母质粒、植物细胞病毒、哺乳动物细胞病毒或其他载体。总之，只要能在宿主体内复制和稳定，任何质粒和载体都可以用。表达载体的一个重要特征是通常含有复制起点、启动子、标记基因和翻译控制元件。
包含上述的适当核酸序列以及适当启动子或者控制序列的载体，可以用于转化适当的宿主细胞，以使其能够表达CRIg功能区蛋白变体。
CRIg功能区蛋白变体的应用
本发明的主要贡献不仅在于公开了多个CRIg功能区蛋白变体，同时还在于验证了这些CRIg功能区蛋白变体的补体抑制活性。
实验证明，本发明公开的CRIg变体重组蛋白对补体激活的抑制功能比天然的CRIg重组蛋白更强，可应用于制备靶向抑制补体激活的抑制剂；也可应用于制备靶向抑制补体激活的药物，提供疗效更优的药物，以应用于多种与补体异常激活有关疾病的预防和治疗。
药物组合物
本发明还提供一种用于制备靶向抑制补体激活的药物组合物，所述的药物组合物包括：本发明所述的CRIg功能区蛋白变体或编码其的核酸，或含有该核酸的表达载体或表达该CRIg功能区蛋白变体的重组细胞；以及药学上或生理学上可接受的载体。
合适的药学上可接受的载体是本领域普通技术人员所熟知的。在Remington’sPharmaceutical Sciences中可找到关于药学上可接受的载体的充分说明。在组合物中药学上可接受的载体可含有液体，如水、磷酸盐缓冲液、ringer溶液、生理盐水、平衡盐溶液、甘油或山梨醇等。另外，这些载体中还可能存在辅助性的物质，如润滑剂、助流剂、润湿剂或乳化剂、pH缓冲物质和稳定剂，如白蛋白等。
下面将结合附图1至图6以及具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。
实施例1、CRIg-Fc-Mutant重组蛋白表达载体的构建、真核表达和纯化
1.仪器与材料
Mastercycler pro-Eppendorf PCR仪(德国Eppendorf公司)，DK-8D型电热恒温水槽(上海精宏实验设备有限公司)，CO2细胞培养箱(美国Thermo Scientific公司)，离心机(Eppendorf/Beckman)。
2.实验方法
2.1基因克隆和载体构建
提取人淋巴瘤U937细胞的总RNA，反转录为cDNA，PCR扩增CRIg基因的胞外结构域；插入到pfuseIgG4Fc2真核表达载体中，双向测序鉴定插入序列，载体命名为CRIg-pfuseIgG4Fc2。
2.1.1引物设计
设计引物，以构建表达CRIg-Fc-Mu1～5的表达载体，引物如下：
Mu1-F：GCTGTGAATCTTCCCTGCACCTA(SEQ ID NO：15)
Mu1-R：CCCTTTCCAAGGTCCTGTTACA(SEQ ID NO：16)
Mu2-F：GCTCTTCCCTGCACCTATGACCC(SEQ ID NO：17)
Mu2-R：CACATCCCCTTTCCAAGGTCCTGT(SEQ ID NO：18)
Mu3-F：GCAGCCTACACCCAAGTCTTGGTGAA(SEQ ID NO：19)
Mu3-R：CAGGGGGTCATAGGTGCAGGGAAG(SEQ ID NO：20)
Mu4-F：GCATTGAGCACCCTGGAGATGGATGA(SEQ ID NO：21)
Mu4-R：GAGGGATACATCTCCTGGAACCT(SEQ ID NO：22)
Mu5-F：GCTGCTGGCAACCAAGTCGTGA(SEQ ID NO：23)
Mu5-R：AGTCTGCCAGGTGACTTCACAC(SEQ ID NO：24)
2.1.2通过上述引物，利用TOYOBO KOD-Plus-Mutagenesis Kit构建质粒不同位点氨基酸取代的CRIg-Fc-Mutant重组蛋白的表达载体，即表达CRIg-Fc-Mu1～5的表达载体，且经测序鉴定，各突变型重组蛋白表达质粒均成功构建。
相关序列如下：
CRIg-Fc-Mu1变体重组蛋白的胞外功能区：核酸序列如SEQ ID NO：5；氨基酸序列如SEQ ID NO：6所示；
CRIg-Fc-Mu2变体重组蛋白的胞外功能区：核酸序列如SEQ ID NO：7；氨基酸序列如SEQ ID NO：8所示；
CRIg-Fc-Mu3变体重组蛋白的胞外功能区：核酸序列如SEQ ID NO：9；氨基酸序列如SEQ ID NO：10所示；
CRIg-Fc-Mu4变体重组蛋白的胞外功能区：核酸序列如SEQ ID NO：11；氨基酸序列如SEQ ID NO：12所示；
CRIg-Fc-Mu5变体重组蛋白的胞外功能区：核酸序列如SEQ ID NO：13；氨基酸序列如SEQ ID NO：14所示。
2.2蛋白表达及纯化
2.2.1实验试剂
结合/洗杂缓冲液：0.15M NaCl，20mM Na2HPO4，pH7.0；
洗脱液：0.1M甘氨酸，pH 3.0；
中和液：1M Tris-HCl，pH 8.5。
2.2.2实验步骤
1)蛋白表达：在15cm培养皿中铺板293FT细胞，细胞密度约为80％时转染，在1mloptiMEM中加入20ug表达野生型或突变型CRIg-Fc-Mutant的载体质粒，20μl Tenfect DNAtransfection reagent(TEYE Corporation,Shanghai,China)，混匀孵育30min后加入细胞培养基中。5h后换Freestyle(gibco)培养基，72h后收集培养基上清。
2)浓缩：上清用0.22mm滤膜过滤后用30kD超滤管浓缩至约2ml。
3)将Protein A Agarose Resin(Yeasen)装入合适的层析空柱中，注意避免产生气泡。
4)平衡：用5倍柱体积的结合缓冲液平衡层析柱，使填料处于与目的蛋白相同的缓冲体系下，起到保护蛋白的作用。
5)上样：将样品加到平衡好的Protein A Agarose Resin中，保证目的蛋白与树脂充分接触，提高目的蛋白的回收率，收集流出液，以待检测。
6)洗杂：用10-15倍柱体积的洗杂缓冲液进行清洗，去除非特异性吸附的杂蛋白，收集洗杂液，以待检测。
7)洗脱：使用5倍柱体积的洗脱缓冲液，收集洗脱液，即目的蛋白组分。
8)置换：将目的蛋白加入含有15ml PBS的超滤管中浓缩，重复三次，使目的蛋白溶解于PBS中便于定量及后续实验。
9)清洗及保存：依次使用3倍柱体积的结合Buffer和5倍柱体积的去离子水平衡填料，最后再用5倍柱体积的20％的乙醇平衡，然后保存在等体积的20％的乙醇中，置于4℃保存，防止填料被细菌污染。
10)SDS-PAGE检测
将纯化过程中得到的样品(包括原始样品、流出组分、洗杂及洗脱组分等)利用SDS-PAGE进行检测，判定其纯化效果
3.实验结果：
本实施例中，与IgG4-Fc段偶联的野生型重组蛋白CRIg-Fc-wt和5种突变型重组蛋白CRIg-Fc-Mu1～5的蛋白分子量大小均为39kDa。结果如图1所示，考马斯亮蓝染色进一步证实各突变型重组蛋白的成功表达。
实施例2、不同CRIg-Fc-Mutant重组蛋白的补体抑制活性测定
1.仪器与材料
Wieslab补体系统旁路途径试剂盒(SVAR)，Synergy H4全功能酶标仪(Bio Tek)。
2.实验方法
使用Wieslab补体系统旁路途径试剂盒来评估不同CRIg-Fc-Mu1～5重组蛋白对补体激活的抑制效果。
2.1洗涤液的配制
将装有浓缩洗涤液的小瓶置于37℃水浴中，直到晶体溶解后再稀释洗涤液。30ml的30×洗涤液用870毫升蒸馏水稀释。储存于2～8℃。
2.2建立阳性对照
将所有冻干的材料轻拍至瓶底，取下瓶盖，立即加入200μl蒸馏水。重新盖上瓶盖，在冰上放置5分钟，偶尔轻轻摇动或涡流，直至完全溶解。以与待测样本相同的方式稀释建立对照。
2.3稀释血清
将冷冻的血清轻轻放入37℃的水浴中，部分解冻后立即将试管放在冰上直到完全融化。在涡流混合器上混匀。用AP稀释液稀释血清(340μL稀释液+20μL血清)。稀释的血清在分析前可在室温下放置最多60分钟。
2.4孵化样本
吸液量100μL/孔，分别加入空白对照(稀释液)、阳性对照(PC)、阴性对照(NC)及待测样本。37℃烘箱孵育60-70分钟。将板子倒空，用300μL洗涤液冲洗3次，最后一次洗完后，用吸水纸轻敲贴片，将孔清空。
2.5结合偶联
每孔加100μL conjugate buffer。室温孵育30分钟。洗涤3次。
2.6添加底物溶液
每孔加入100μL底物溶液，室温孵育30分钟。每孔加入100μL 5mM EDTA终止反应。
2.7读取结果并计算
在酶标仪上读出405nm处的吸光度。计算样品、PC和NC的平均OD405nm值，并计算补体活性，计算公式如下：(样品－NC)/(PC－NC)×100％。
3.实验结果
结果如图2至图6所示，五种CRIg-Fc-mutant重组蛋白在10nM和100nM浓度时补体抑制活性均明显优于野生型CRIg-Fc-wt重组蛋白(*P<0.05；**P<0.01)，其中，CRIg-Fc-Mu2、CRIg-Fc-Mu3和CRIg-Fc-Mu5重组蛋白的补体抑制活性更优，它们在100nM浓度时，能使补体活性降到很低。
综上所述，本发明公开了CRIg胞外功能区的多个氨基酸取代位点，并示例性的提供了多个CRIg功能区蛋白变体，相较于天然序列的CRIg功能区蛋白，这些变体对补体激活的抑制功能更强，可应用于制备靶向抑制补体激活的抑制剂或药物，从而预防、治疗多种与补体异常激活有关的疾病。
尽管本发明的内容已经通过上述优选实施例作了详细介绍，但应当认识到上述的描述不应被认为是对本发明的限制。在本领域技术人员阅读了上述内容后，对于本发明的多种修改和替代都将是显而易见的。因此，本发明的保护范围应由所附的权利要求来限定。
序列表
<110> 复旦大学
珠海复旦创新研究院
<120> CRIg 功能区蛋白变体及其应用
<141> 2021-07-28
<160> 24
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1200
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
atggggatct tactgggcct gctactcctg gggcacctaa cagtggacac ttatggccgt 60
cccatcctgg aagtgccaga gagtgtaaca ggaccttgga aaggggatgt gaatcttccc 120
tgcacctatg accccctgca aggctacacc caagtcttgg tgaagtggct ggtacaacgt 180
ggctcagacc ctgtcaccat ctttctacgt gactcttctg gagaccatat ccagcaggca 240
aagtaccagg gccgcctgca tgtgagccac aaggttccag gagatgtatc cctccaattg 300
agcaccctgg agatggatga ccggagccac tacacgtgtg aagtcacctg gcagactcct 360
gatggcaacc aagtcgtgag agataagatt actgagctcc gtgtccagaa actctctgtc 420
tccaagccca cagtgacaac tggcagcggt tatggcttca cggtgcccca gggaatgagg 480
attagccttc aatgccaggc tcggggttct cctcccatca gttatatttg gtataagcaa 540
cagactaata accaggaacc catcaaagta gcaaccctaa gtaccttact cttcaagcct 600
gcggtgatag ccgactcagg ctcctatttc tgcactgcca agggccaggt tggctctgag 660
cagcacagcg acattgtgaa gtttgtggtc aaagactcct caaagctact caagaccaag 720
actgaggcac ctacaaccat gacatacccc ttgaaagcaa catctacagt gaagcagtcc 780
tgggactgga ccactgacat ggatggctac cttggagaga ccagtgctgg gccaggaaag 840
agcctgcctg tctttgccat catcctcatc atctccttgt gctgtatggt ggtttttacc 900
atggcctata tcatgctctg tcggaagaca tcccaacaag agcatgtcta cgaagcagcc 960
agggcacatg ccagagaggc caacgactct ggagaaacca tgagggtggc catcttcgca 1020
agtggctgct ccagtgatga gccaacttcc cagaatctgg gcaacaacta ctctgatgag 1080
ccctgcatag gacaggagta ccagatcatc gcccagatca atggcaacta cgcccgcctg 1140
ctggacacag ttcctctgga ttatgagttt ctggccactg agggcaaaag tgtctgttaa 1200
<210> 2
<211> 399
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Gly Ile Leu Leu Gly Leu Leu Leu Leu Gly His Leu Thr Val Asp
1 5 10 15
Thr Tyr Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro
20 25 30
Trp Lys Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly
35 40 45
Tyr Thr Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro
50 55 60
Val Thr Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala
65 70 75 80
Lys Tyr Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val
85 90 95
Ser Leu Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr
100 105 110
Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp
115 120 125
Lys Ile Thr Glu Leu Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr
130 135 140
Val Thr Thr Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg
145 150 155 160
Ile Ser Leu Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile
165 170 175
Trp Tyr Lys Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr
180 185 190
Leu Ser Thr Leu Leu Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser
195 200 205
Tyr Phe Cys Thr Ala Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp
210 215 220
Ile Val Lys Phe Val Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys
225 230 235 240
Thr Glu Ala Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr
245 250 255
Val Lys Gln Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly
260 265 270
Glu Thr Ser Ala Gly Pro Gly Lys Ser Leu Pro Val Phe Ala Ile Ile
275 280 285
Leu Ile Ile Ser Leu Cys Cys Met Val Val Phe Thr Met Ala Tyr Ile
290 295 300
Met Leu Cys Arg Lys Thr Ser Gln Gln Glu His Val Tyr Glu Ala Ala
305 310 315 320
Arg Ala His Ala Arg Glu Ala Asn Asp Ser Gly Glu Thr Met Arg Val
325 330 335
Ala Ile Phe Ala Ser Gly Cys Ser Ser Asp Glu Pro Thr Ser Gln Asn
340 345 350
Leu Gly Asn Asn Tyr Ser Asp Glu Pro Cys Ile Gly Gln Glu Tyr Gln
355 360 365
Ile Ile Ala Gln Ile Asn Gly Asn Tyr Ala Arg Leu Leu Asp Thr Val
370 375 380
Pro Leu Asp Tyr Glu Phe Leu Ala Thr Glu Gly Lys Ser Val Cys
385 390 395
<210> 3
<211> 357
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
ggccgtccca tcctggaagt gccagagagt gtaacaggac cttggaaagg ggatgtgaat 60
cttccctgca cctatgaccc cctgcaaggc tacacccaag tcttggtgaa gtggctggta 120
caacgtggct cagaccctgt caccatcttt ctacgtgact cttctggaga ccatatccag 180
caggcaaagt accagggccg cctgcatgtg agccacaagg ttccaggaga tgtatccctc 240
caattgagca ccctggagat ggatgaccgg agccactaca cgtgtgaagt cacctggcag 300
actcctgatg gcaaccaagt cgtgagagat aagattactg agctccgtgt ccagaaa 357
<210> 4
<211> 119
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys
1 5 10 15
Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr
20 25 30
Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr
35 40 45
Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr
50 55 60
Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu
65 70 75 80
Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu
85 90 95
Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile
100 105 110
Thr Glu Leu Arg Val Gln Lys
115
<210> 5
<211> 357
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
ggccgtccca tcctggaagt gccagagagt gtaacaggac cttggaaagg ggctgtgaat 60
cttccctgca cctatgaccc cctgcaaggc tacacccaag tcttggtgaa gtggctggta 120
caacgtggct cagaccctgt caccatcttt ctacgtgact cttctggaga ccatatccag 180
caggcaaagt accagggccg cctgcatgtg agccacaagg ttccaggaga tgtatccctc 240
caattgagca ccctggagat ggatgaccgg agccactaca cgtgtgaagt cacctggcag 300
actcctgatg gcaaccaagt cgtgagagat aagattactg agctccgtgt ccagaaa 357
<210> 6
<211> 119
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys
1 5 10 15
Gly Ala Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr
20 25 30
Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr
35 40 45
Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr
50 55 60
Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu
65 70 75 80
Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu
85 90 95
Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile
100 105 110
Thr Glu Leu Arg Val Gln Lys
115
<210> 7
<211> 357
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
ggccgtccca tcctggaagt gccagagagt gtaacaggac cttggaaagg ggatgtggct 60
cttccctgca cctatgaccc cctgcaaggc tacacccaag tcttggtgaa gtggctggta 120
caacgtggct cagaccctgt caccatcttt ctacgtgact cttctggaga ccatatccag 180
caggcaaagt accagggccg cctgcatgtg agccacaagg ttccaggaga tgtatccctc 240
caattgagca ccctggagat ggatgaccgg agccactaca cgtgtgaagt cacctggcag 300
actcctgatg gcaaccaagt cgtgagagat aagattactg agctccgtgt ccagaaa 357
<210> 8
<211> 119
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys
1 5 10 15
Gly Asp Val Ala Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr
20 25 30
Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr
35 40 45
Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr
50 55 60
Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu
65 70 75 80
Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu
85 90 95
Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile
100 105 110
Thr Glu Leu Arg Val Gln Lys
115
<210> 9
<211> 357
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
ggccgtccca tcctggaagt gccagagagt gtaacaggac cttggaaagg ggatgtgaat 60
cttccctgca cctatgaccc cctggcagcc tacacccaag tcttggtgaa gtggctggta 120
caacgtggct cagaccctgt caccatcttt ctacgtgact cttctggaga ccatatccag 180
caggcaaagt accagggccg cctgcatgtg agccacaagg ttccaggaga tgtatccctc 240
caattgagca ccctggagat ggatgaccgg agccactaca cgtgtgaagt cacctggcag 300
actcctgatg gcaaccaagt cgtgagagat aagattactg agctccgtgt ccagaaa 357
<210> 10
<211> 119
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys
1 5 10 15
Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Ala Ala Tyr Thr
20 25 30
Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr
35 40 45
Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr
50 55 60
Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu
65 70 75 80
Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu
85 90 95
Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile
100 105 110
Thr Glu Leu Arg Val Gln Lys
115
<210> 11
<211> 357
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
ggccgtccca tcctggaagt gccagagagt gtaacaggac cttggaaagg ggatgtgaat 60
cttccctgca cctatgaccc cctgcaaggc tacacccaag tcttggtgaa gtggctggta 120
caacgtggct cagaccctgt caccatcttt ctacgtgact cttctggaga ccatatccag 180
caggcaaagt accagggccg cctgcatgtg agccacaagg ttccaggaga tgtatccctc 240
gcattgagca ccctggagat ggatgaccgg agccactaca cgtgtgaagt cacctggcag 300
actcctgatg gcaaccaagt cgtgagagat aagattactg agctccgtgt ccagaaa 357
<210> 12
<211> 119
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys
1 5 10 15
Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr
20 25 30
Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr
35 40 45
Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr
50 55 60
Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu
65 70 75 80
Ala Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu
85 90 95
Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile
100 105 110
Thr Glu Leu Arg Val Gln Lys
115
<210> 13
<211> 357
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
ggccgtccca tcctggaagt gccagagagt gtaacaggac cttggaaagg ggatgtgaat 60
cttccctgca cctatgaccc cctgcaaggc tacacccaag tcttggtgaa gtggctggta 120
caacgtggct cagaccctgt caccatcttt ctacgtgact cttctggaga ccatatccag 180
caggcaaagt accagggccg cctgcatgtg agccacaagg ttccaggaga tgtatccctc 240
caattgagca ccctggagat ggatgaccgg agccactaca cgtgtgaagt cacctggcag 300
actgctgctg gcaaccaagt cgtgagagat aagattactg agctccgtgt ccagaaa 357
<210> 14
<211> 119
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys
1 5 10 15
Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr
20 25 30
Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr
35 40 45
Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr
50 55 60
Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu
65 70 75 80
Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu
85 90 95
Val Thr Trp Gln Thr Ala Ala Gly Asn Gln Val Val Arg Asp Lys Ile
100 105 110
Thr Glu Leu Arg Val Gln Lys
115
<210> 15
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 15
gctgtgaatc ttccctgcac cta 23
<210> 16
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
ccctttccaa ggtcctgtta ca 22
<210> 17
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 17
gctcttccct gcacctatga ccc 23
<210> 18
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 18
cacatcccct ttccaaggtc ctgt 24
<210> 19
<211> 26
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 19
gcagcctaca cccaagtctt ggtgaa 26
<210> 20
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
cagggggtca taggtgcagg gaag 24
<210> 21
<211> 26
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 21
gcattgagca ccctggagat ggatga 26
<210> 22
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 22
gagggataca tctcctggaa cct 23
<210> 23
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 23
gctgctggca accaagtcgt ga 22
<210> 24
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 24
agtctgccag gtgacttcac ac 22
Claims (9)
1.一种CRIg功能区蛋白变体，其特征在于，所述CRIg功能区蛋白变体的氨基酸序列如SEQ ID NO：8、SEQ ID NO：10或SEQ ID NO：14所示。
2.一种如权利要求1所述的CRIg功能区蛋白变体在制备靶向抑制补体激活的抑制剂中的应用，其特征在于，所述抑制剂用于非治疗目的。
3.一种如权利要求1所述的CRIg功能区蛋白变体在制备防治与补体异常激活有关疾病的药物中的应用，其特征在于，所述疾病为小鼠关节炎。
4.一种核酸，其特征在于，所述的核酸编码权利要求1所述的CRIg功能区蛋白变体。
5.一种表达载体，其特征在于，所述的表达载体含有权利要求4所述的核酸。
6.一种重组细胞，其特征在于，所述的重组细胞含有权利要求5所述的表达载体或其基因组中包含权利要求4所述的核酸。
7.权利要求4所述的核酸，或权利要求5所述的表达载体，或权利要求6所述的重组细胞在制备靶向抑制补体激活的抑制剂或防治与补体异常激活有关疾病的药物中的应用，其特征在于，所述抑制剂用于非治疗目的，所述疾病为小鼠关节炎。
8.一种制备权利要求1所述的CRIg功能区蛋白变体的方法，其特征在于，所述方法包括：培养权利要求6所述的重组细胞，从而重组表达权利要求1所述的CRIg功能区蛋白变体。
9.一种用于靶向抑制补体激活的药物组合物，其特征在于，所述的药物组合物包括：权利要求1所述的CRIg功能区蛋白变体，或权利要求4所述的核酸，或权利要求5所述的表达载体，或权利要求6所述的重组细胞；以及药学上或生理学上可接受的载体。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110856994.7A CN113583107B (zh) | 2021-07-28 | 2021-07-28 | CRIg功能区蛋白变体及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110856994.7A CN113583107B (zh) | 2021-07-28 | 2021-07-28 | CRIg功能区蛋白变体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113583107A CN113583107A (zh) | 2021-11-02 |
| CN113583107B true CN113583107B (zh) | 2023-11-10 |
Family
ID=78251005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110856994.7A Active CN113583107B (zh) | 2021-07-28 | 2021-07-28 | CRIg功能区蛋白变体及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113583107B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101107005A (zh) * | 2004-10-12 | 2008-01-16 | 健泰科生物技术公司 | 用于预防和治疗补体相关紊乱的CRIg多肽 |
| CN104231085A (zh) * | 2013-09-05 | 2014-12-24 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
| CN104558151A (zh) * | 2008-05-06 | 2015-04-29 | 健泰科生物技术公司 | 亲和力成熟的CRIg变体 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776573B2 (en) * | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
-
2021
- 2021-07-28 CN CN202110856994.7A patent/CN113583107B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101107005A (zh) * | 2004-10-12 | 2008-01-16 | 健泰科生物技术公司 | 用于预防和治疗补体相关紊乱的CRIg多肽 |
| CN104558151A (zh) * | 2008-05-06 | 2015-04-29 | 健泰科生物技术公司 | 亲和力成熟的CRIg变体 |
| CN104231085A (zh) * | 2013-09-05 | 2014-12-24 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
Non-Patent Citations (3)
| Title |
|---|
| Improving Therapeutic Efficacy of a Complement Receptor by Structure-based Affinity Maturation;Bing Li等;THE JOURNAL OF BIOLOGICAL CHEMISTRY;第284卷(第51期);第35605-35611页 * |
| Structure of C3b in complex with CRIg gives insights into regulation of complement activatio;Christian Wiesman等;nature;第444卷;第217-220页 * |
| 新型免疫调节分子VSIG4介导免疫清除及炎症的研究进展;金美花;陈永文;李春实;;免疫学杂志;第30卷(第12期);第1108-1112页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113583107A (zh) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6947888B2 (ja) | クロストリジウム・ヒストリチクム（ｃｌｏｓｔｒｉｄｉｕｍ ｈｉｓｔｏｌｙｔｉｃｕｍ）酵素およびその使用のための方法 | |
| CA2023779A1 (en) | Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders | |
| AU3433189A (en) | Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression | |
| JP2005336202A (ja) | マクロファージ炎症蛋白変種 | |
| CN109071678A (zh) | 神经生长因子融合蛋白、制备方法及其用途 | |
| NO301480B1 (no) | Fremgangsmåte for enzymatisk fremstilling av basisk fibroblastfaktor | |
| JP2018535964A (ja) | 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置 | |
| JP2024023297A (ja) | 可溶化アピラーゼ、方法及び使用 | |
| JPH05503512A (ja) | 白血球接着阻害因子としての［ａｌａ ｉｌ―８］↓７↓７ | |
| WO1998029446A1 (fr) | Neuropeptides provenant du scorpion | |
| AU2014236728A1 (en) | Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides | |
| HRP20030215A2 (en) | Chemokine mutants in the tratment of multiple sclerosis | |
| CN113583107B (zh) | CRIg功能区蛋白变体及其应用 | |
| CN105017410A (zh) | 一种b区部分缺失型重组人凝血因子ⅷ | |
| CN101280001A (zh) | 人SDF-1α的制备及由此获得的人SDF-1α及其用途 | |
| US6395875B1 (en) | Recombinant soluble adenovirus receptor | |
| JPH04503960A (ja) | 高発現宿主細胞系からの生物活性血小板由来成長因子の産生 | |
| Holtet et al. | Receptor‐binding domain of human α2‐macroglobulin Expression, folding and biochemical characterization of a high‐affinity recombinant derivative | |
| CN106496329B (zh) | 一种含有胶原蛋白结合结构域的融合蛋白 | |
| AU2008256550B2 (en) | VEGF-D mutants and their use | |
| KR101651330B1 (ko) | 세포투과성이 우수한 ｔａｔ－ａ２０ 융합단백질의 제조방법 및 이의 용도 | |
| KR20080026085A (ko) | 곤충세포에서 제조한 재조합 ｅ-셀렉틴 | |
| JPH02273193A (ja) | 組換えインターロイキン―２融合蛋白質類 | |
| KR20230015418A (ko) | 인터루킨-1 수용체 길항제 및 이를 포함하는 융합 단백질 | |
| KR101106262B1 (ko) | 인간 호메오 도메인 유전자 유래의 단백질 도입 도메인 및 이를 이용한 단백질 도입 벡터 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |